hotspot -WSS

hotspot

author：comprehensive 2025-09-30 22:37:55 - browse：1721

The experimental Alzheimer’s drug lecanemab, hailed after it slowed patients’ cognitive decline in a clinical trial, may have contributed to the death in June of a patient in the study, STAT has learned.

One investigator on the study flagged the death, noting it came after the patient experienced bleeding in the brain, and concluded it was related to the drug, according to documents obtained by STAT. Eisai, the drugmaker behind lecanemab, disagreed, pointing to other possible factors, including a series of setbacks in preceding months — multiple falls, a heart attack, a respiratory infection, and mini-stroke-like events.

Though still under investigation, the death suggests that new medicines to treat Alzheimer’s, like medicines to treat anything else, will come with their own side effects and costs. It also raises the importance of waiting for the full lecanemab data before drawing conclusions based on the positive press release put out by Eisai and its partner Biogen last month.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： Did the public have the right to know Arthur Ashe had AIDS?

WSS

Listen: Biogen's messy board & Laronde's data problem

Innovation in antibiotics is ailing. 'Brain drain' may kill it

With trial win, GSK could get blood cancer drug back on market

Option Care buys Amedisys in $3.6 billion home care deal

Australia's humpback populations rebound raising hopes of marine scientists

How to increase colonoscopy rates? Looks like an AI can help

Wikipedia

hotspot

leisure time

Medical records are filled with copy

Did the public have the right to know Arthur Ashe had AIDS?

The high cost of giving birth even with insurance

Ukraine, Russia accuse each other of planning to attack Europe's biggest nuclear plant

In Memoriam: Notable people who died in 2023

ASCO Daily Recap: Safety data from Novartis, survival from Pfizer

Trump demands the U.S. pay no more for drugs than other countries … again

Listen: Biogen's messy board & Laronde's data problem

New air purifier tech could be key to improving indoor air quality

Can food be medicine? And other questions about a new push

focus

Let's speed up science by embracing open access publishing

When is a doctor not a doctor? Try when patients address women doctors

ASCO: AstraZeneca says CAR

At ASCO, pharma leaders speak of advances in 'smart bomb' drugs

Van's Gluten Free Original Waffles recalled for possible wheat allergen

4th of July breaks record for highest global temperature ever measured

leisure time

Wikipedia

focus

Wikipedia